Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27282019 | 0.85 | — | — | |
| SCHEMBL27281478 | 0.85 | — | — | |
| SCHEMBL14818910 | 0.85 | — | — | |
| SCHEMBL26521285 | 0.82 | ACHE (0.39) | OPRM1SMN1; SMN2 | |
| SCHEMBL1710042 | 0.81 | KDM4E (0.37) | KDM4EGAATSHROPRM1OPRD1 | |
| SCHEMBL13564381 | 0.80 | KDM4E (0.40) | KDM4E | |
| SCHEMBL16508773 | 0.79 | KDM4E (0.36) | KDM4EGAATSHROPRM1OPRD1 | |
| SCHEMBL6922492 | 0.78 | GAA (0.38) | KDM4EGAATSHROPRM1OPRD1 | |
| SCHEMBL25794064 | 0.77 | KDM4E (0.35) | KDM4EGAATSHROPRM1OPRD1 | |
| SCHEMBL27360376 | 0.77 | S1PR1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| EP-4393919-A1 | LSD1 MODULATORS | Exscientia Al Limited (GB) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024015863-A1 | CBL-B INHIBITOR, COMPOSITIONS COMPRISING A CBL-B INHIBITOR IN A METHOD OF TREATING A DISEASE ASSOCIATED WITH CELL PROLIFERATION | HOTSPOT THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230212172-A1 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | SAINT LOUIS UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022022600-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-02-03 | — | — | WO | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2015-03-05 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | KDM4E 2063/4885GAA 766/4885TSHR 859/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | KDM4E 674/4885GAA 2982/4885TSHR 2238/4885 |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | KDM4E 2515/4885GAA 2517/4885TSHR 2607/4885 |
| US-20230212172-A1 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | AADAC, PAICS, PNPO | KDM4E 3745/4885GAA 2827/4885TSHR 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.